New daily pill shows promise against Alzheimer's and Parkinson's disease
Buntanetap, a pill being tested in the US, improved memory in some Alzheimer's patients and has previously shown benefits in Parkinson's disease.
A new experimental drug for Alzheimer's disease has shown encouraging results in helping some patients maintain their memory and thinking abilities, according to findings from a recent clinical trial.
The drug, called buntanetap, was tested in 351 people with mild to moderate Alzheimer's disease across 54 medical centres in the United States.
Researchers found that while the study did not achieve its main goals, a subgroup of patients with confirmed Alzheimer's-related brain changes appeared to benefit from the treatment.
The study's main goals were to determine whether buntanetap could improve memory and thinking abilities in Alzheimer's patients and whether it could improve their overall clinical condition. However, after 12 weeks of treatment, the drug did not significantly outperform a placebo in the overall study population, causing the trial to miss its primary endpoints.
Researchers believe the results may have been affected because nearly 40% of participants lacked the biological markers typically associated with Alzheimer's disease. When the analysis was limited to patients with biomarker-confirmed Alzheimer's, particularly those with mild disease, the drug showed dose-dependent improvements in cognition, prompting a larger Phase 3 trial.
Alzheimer's disease is the most common form of dementia and affects millions of people worldwide. It causes memory loss, confusion, difficulty in thinking, and changes in behaviour. While some newer treatments can slow the disease, there is still no cure.
NEW PILL FOR ALZHEIMER'S
Buntanetap is a daily pill designed to reduce the build-up of harmful proteins in the brain that are believed to contribute to Alzheimer's disease.
Unlike some currently available drugs that target only one protein, buntanetap is designed to act on several proteins linked to brain damage.
The three-month study tested three different doses of the drug against a placebo, a dummy treatment. Researchers reported that the drug was generally safe and well tolerated. No serious side effects linked to the medication were observed.
Although the overall trial results were disappointing, researchers later discovered that nearly 40% of participants did not have the biological signs typically seen in Alzheimer's disease. This may have affected the study's outcome.
When researchers focused only on patients who showed clear signs of Alzheimer's disease, they found that those with mild disease experienced improvements in memory and thinking skills compared to those receiving the placebo.
The benefits appeared to increase with higher doses of the drug.
Researchers also found signs that buntanetap may reduce inflammation and damage to brain cells, although more studies are needed to confirm these findings.
The drug has already been tested in more than 1,000 people across 13 clinical trials, including studies involving patients with Alzheimer's and Parkinson's disease.
Previous studies have also suggested it could help improve cognitive function.
SAME PILL FOR PARKINSON'S
The researchers said buntanetap has also shown encouraging results in people with Parkinson's disease, another condition that affects the brain and nervous system.
In earlier studies, patients with Parkinson's who received the drug showed improvements in thinking abilities, movement and mental processing speed. A recently completed mid-stage trial also found improvements in cognitive function among Parkinson's patients.
These findings have raised hopes that the drug could potentially be useful in treating multiple neurodegenerative diseases, although larger studies are still needed to confirm the benefits.
"Buntanetap has now been tested in more than 1,000 participants, including healthy volunteers and patients with Alzheimer's and Parkinson's disease," the researchers noted, adding that the drug has demonstrated a favourable safety profile across studies.
BUT, IT'S TOO SOON TO TELL
But the findings are still preliminary.
The positive results came from a smaller subgroup analysis rather than the main trial results.
A larger Phase 3 clinical trial involving around 760 patients is now underway to determine whether buntanetap can consistently slow cognitive decline and improve symptoms in people with early Alzheimer's disease.
If successful, the drug could offer a new treatment option for a disease that currently has very limited therapies.
A new experimental drug for Alzheimer's disease has shown encouraging results in helping some patients maintain their memory and thinking abilities, according to findings from a recent clinical trial.
The drug, called buntanetap, was tested in 351 people with mild to moderate Alzheimer's disease across 54 medical centres in the United States.
Researchers found that while the study did not achieve its main goals, a subgroup of patients with confirmed Alzheimer's-related brain changes appeared to benefit from the treatment.
The study's main goals were to determine whether buntanetap could improve memory and thinking abilities in Alzheimer's patients and whether it could improve their overall clinical condition. However, after 12 weeks of treatment, the drug did not significantly outperform a placebo in the overall study population, causing the trial to miss its primary endpoints.
Researchers believe the results may have been affected because nearly 40% of participants lacked the biological markers typically associated with Alzheimer's disease. When the analysis was limited to patients with biomarker-confirmed Alzheimer's, particularly those with mild disease, the drug showed dose-dependent improvements in cognition, prompting a larger Phase 3 trial.
Alzheimer's disease is the most common form of dementia and affects millions of people worldwide. It causes memory loss, confusion, difficulty in thinking, and changes in behaviour. While some newer treatments can slow the disease, there is still no cure.
NEW PILL FOR ALZHEIMER'S
Buntanetap is a daily pill designed to reduce the build-up of harmful proteins in the brain that are believed to contribute to Alzheimer's disease.
Unlike some currently available drugs that target only one protein, buntanetap is designed to act on several proteins linked to brain damage.
The three-month study tested three different doses of the drug against a placebo, a dummy treatment. Researchers reported that the drug was generally safe and well tolerated. No serious side effects linked to the medication were observed.
Although the overall trial results were disappointing, researchers later discovered that nearly 40% of participants did not have the biological signs typically seen in Alzheimer's disease. This may have affected the study's outcome.
When researchers focused only on patients who showed clear signs of Alzheimer's disease, they found that those with mild disease experienced improvements in memory and thinking skills compared to those receiving the placebo.
The benefits appeared to increase with higher doses of the drug.
Researchers also found signs that buntanetap may reduce inflammation and damage to brain cells, although more studies are needed to confirm these findings.
The drug has already been tested in more than 1,000 people across 13 clinical trials, including studies involving patients with Alzheimer's and Parkinson's disease.
Previous studies have also suggested it could help improve cognitive function.
SAME PILL FOR PARKINSON'S
The researchers said buntanetap has also shown encouraging results in people with Parkinson's disease, another condition that affects the brain and nervous system.
In earlier studies, patients with Parkinson's who received the drug showed improvements in thinking abilities, movement and mental processing speed. A recently completed mid-stage trial also found improvements in cognitive function among Parkinson's patients.
These findings have raised hopes that the drug could potentially be useful in treating multiple neurodegenerative diseases, although larger studies are still needed to confirm the benefits.
"Buntanetap has now been tested in more than 1,000 participants, including healthy volunteers and patients with Alzheimer's and Parkinson's disease," the researchers noted, adding that the drug has demonstrated a favourable safety profile across studies.
BUT, IT'S TOO SOON TO TELL
But the findings are still preliminary.
The positive results came from a smaller subgroup analysis rather than the main trial results.
A larger Phase 3 clinical trial involving around 760 patients is now underway to determine whether buntanetap can consistently slow cognitive decline and improve symptoms in people with early Alzheimer's disease.
If successful, the drug could offer a new treatment option for a disease that currently has very limited therapies.
